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lecular biomarkers in Se´zary cells that could be useful as additional diagnostic criteria. In this European
multicenter study, the sensitivity and specificity of these immunophenotypic and recently proposed but
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expression using custom-made quantitative PCR plates. Experiments were performed in duplicate in two
independent centers using standard operating procedures with almost identical results. Se´zary
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Se´zary syndrome (SS) is a rare and aggressive type of
cutaneous T-cell lymphoma that is derived from CD4þ
skin-homing memory T cells and characterized by eryth-
roderma, generalized lymphadenopathy, and neoplastic T
cells (Se´zary cells) in the skin, lymph nodes, and peripheral
blood (Wieselthier and Koh, 1990).
Differentiation between SS and erythrodermic inflamma-
tory dermatoses (EID) may be extremely difficult, both clini-
cally and histopathologically, but is very important from
therapeutic and prognostic perspectives. For a long time the
diagnosis was based on demonstration of atypical T cells,
so-called Se´zary cells, in blood smears (Sentis et al., 1986;
Trotter et al., 1997). However, it was shown that Se´zary
cells can also be observed in the peripheral blood of patients
with EID and even in healthy control subjects (Duncan and
Winkelmann, 1978; Meijer et al., 1977). Demonstration of
at least 1,000 Se´zary cells per mm3 was often used as a
decisive criterion, but this was not generally agreed on
(Wieselthier and Koh, 1990). To prevent patients with EIDuthors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.
Table 1. Patients’ clinical characteristics at diagnosis
Characteristic
SS Patients
(n [ 59)
EID Patients
(n [ 19)
Male:female ratio 37:22 16:3
Median age (range), years 65 (32e89) 67 (29e86)
Erythroderma 46/52 (88) 19/19 (100)
Pruritus 45/52 (87) 13/19 (68)
Ectropion 6/52 (12) 1/19 (5)
Hyperkeratosis hand/feet 21/52 (40) 3/19 (16)
Palpable lymphadenopathy 21/52 (40) 4/19 (21)
Lymphadenopathy confirmed by CT scan 17/41 (41) 1/7 (14)
Leukocytes 10.0 109/L 40/56 (71) 5/14 (36)
CD4/CD8 ratio 10.0 53/57 (93) 1/12 (8)
Absolute Se´zary cell count 1,000 mm3 34/43 (79) 0/10 (0)
T-cell clone in peripheral blood 59/59 (100) 1/17 (6)
Identical T-cell clone in blood and skin 32/38 (84) 0/3 (0)
Note. Values are given as n/total (%) unless otherwise noted.
Abbreviations: CT, computed tomography; EID, erythrodermic
inflammatory dermatoses; SS, Se´zary syndrome.
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1997 the European Organization for Research and Treatment
of Cancer group proposed the demonstration of clonal T cells
and the presence of an expanded CD4þ T-cell population
resulting in a CD4/CD8 ratio above 10 as additional criteria
for a diagnosis of SS (Willemze et al., 1997).
At present, the diagnosis of SS is based on clinical pre-
sentation (erythroderma and lymphadenopathy) and
demonstration of a T-cell clone in the peripheral blood
(preferably the same clone in the skin), in combination with
one or more of the following criteria: an absolute Se´zary cell
count greater than 1,000 cells per mm3; loss of T-cell
markers CD2, CD3, CD4, and/or CD5; and/or an expanding
population of CD4þ T-cells leading to a CD4/CD8 ratio of
more than 10 (Swerdlow et al., 2008; Willemze et al., 2005).
However, distinction between SS and EID can still be diffi-
cult, because T-cell clonality can be observed in a sub-
stantial proportion of patients with EID as well, and not all
SS patients have a CD4/CD8 ratio of greater than 10 at first
presentation (Vonderheid, 2006; Vonderheid and Bernengo,
2003).
To solve this diagnostic problem, a number of studies
have attempted to identify characteristic immunopheno-
typic changes and molecular biomarkers in Se´zary cells.
Flow cytometry studies reported loss of CD7 and CD26
expression by Se´zary cells and suggested CD4þCD7 cells
of at least 40% and CD4þCD26 cells of at least 30% as
tentative diagnostic criteria in those difficult cases
(Bernengo et al., 2001; Fierro et al., 2008; Harmon et al.,
1996; Jones et al., 2001; Kelemen et al., 2008; Klemke
et al., 2008; Lima et al., 2003; Olsen et al., 2007; Rappl
et al., 2001; Sokolowska-Wojdylo et al., 2005; Vonder-
heid et al., 2002; Vonderheid and Bernengo, 2003; Wash-
ington et al., 2002).
In addition, recent studies described expression of killer
cell immunoglobulin-like receptors CD158a, CD158b, and
CD158k and the “central memory” T-cell phenotype (CD27þ,
CD45RA, CD45ROþ) as characteristic features of Se´zary
cells (Bagot et al., 2001; Bahler et al., 2008; Campbell et al.,
2010; Dummer et al., 1996; Fierro et al., 2008; Karenko
et al., 2001; Klemke et al., 2008; Lima et al., 2003; Marie-
Cardine et al., 2007; Michel et al., 2013; Poszepczynska-
Guigne et al., 2004). Molecular investigations identified
gain of JUNB, MYC, and loss of MYC antagonists MNT and
MXI1 as recurrent genetic lesions in the SS genome (Mao
et al., 2003; Mao et al., 2008; Vermeer et al., 2008). Gene
expression studies showed increased expression of PLS3,
DNM3, CDO1, TRAIL, CD1D, GATA3, JUNB, TWIST1,
EPHA4, and MYC and decreased expression of STAT4 in
Se´zary cells (Booken et al., 2008; Goswami et al., 2012; Kari
et al., 2003; Mao et al., 2008; Nebozhyn et al., 2006; Su
et al., 2003; Van Doorn et al., 2004).
However, the diagnostic value of these biomarkers in
diagnosing SS has not been investigated thoroughly. More-
over, most biomarkers were identified in small, single-center
studies with a limited number of patients and controls and
have not been confirmed in large independent studies. In
addition, flow cytometry studies have used widely differing
protocols, which impedes interpretation and comparison of
results from different studies.The goal of this European Organization for Research and
Treatment of Cancer multicenter study was to investigate the
sensitivity and specificity of these biomarkers for SS in a large
group of well-defined SS patients compared with EID patients
using standard operating procedures (SOPs).
RESULTS
Patient characteristics
Clinical characteristics at diagnosis of the 59 SS patients and
19 EID patients are summarized in Table 1.
The patients with SS had a T-cell clone in the peripheral
blood (59 of 59), a CD4/CD8 ratio above 10 (53 of 57), and/or
a Se´zary cell count above 1,000 per mm3 (34 of 43, including
all four patients with a CD4/CD8 ratio lower than 10).
One EID patient showed a T-cell clone in the peripheral
blood, and another EID patient had a CD4/CD8 ratio above
10 because of very low numbers of CD8þ T-cells, but none
had a Se´zary cell count above 1,000 mm3 (Table 1).
Flow cytometry
Flow cytometry experiments were performed both in Leiden
and Paris for all 59 SS patients and 19 EID patients. Differ-
ences in flow cytometry results between Leiden and Paris
were greater than 20% in 99.8% of individual assays, and in
these cases an average was used in further analysis. In only 2
of 1,027 assays (0.2%) did the differences in results exceeded
20%, and these were therefore excluded from further
analysis.
In this study, 87% of SS patients (46 of 53) had a CD4/CD8
ratio above 10 at inclusion, compared with 8% of the EID
patients (1 of 12) (sensitivity ¼ 87%, specificity ¼ 92%).
The CD4þ gated lymphocytes were CD3þ and CD8. In
the CD4þ T-cell population, 7 of 59 (12%) SS patients
showed loss for CD2 (median ¼ 45%, range ¼ 32e100%)
and 4 (7%) patients showed diminished expression for CD2
(CD2dim), whereas this was never observed in the 19 EID
patients. One SS patient showed 90% CD5 loss, compared
with none of the EID patients.
In the CD4þ T-cell population, a percentage of CD4þCD7
cells above 40% was found in 32 of 59 (54%) SS patients butwww.jidonline.org 1365
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1366never in EID patients (sensitivity ¼ 54%, specificity ¼ 100%).
In addition, CD7dim was found in 2 of 59 (3%) SS patients,
compared with none of the EID patients.
In the CD4þ T-cell population a percentage of 30% or
more CD4þCD26 cells was found in 51 of 59 (86%) SS
patients but also in 10 of 19 (53%) EID patients (sensitivity ¼
86%, specificity ¼ 47%). When shifting the percentage to
80%, 39 of 59 (66%) SS patients but none of the EID patients
had CD4þCD26 cells of 80% or more in the CD4þ T-cell
population (sensitivity: 66%; specificity: 100%). In addition,
CD26dim was found in 5 of 59 (8%) Se´zary patients and in
one of 19 (5%) EID patients.
Loss of CD26 by more than 80% and/or loss of CD7 by
more than 40% of CD4þ T cells was found in 49 of 59 (83%)
SS patients but was never observed in the EID patients
(sensitivity ¼ 83%, specificity ¼ 100%).
Investigations on CD158k expression showed that more
than 5% of these CD4þ T cells expressed CD158k or
CD158klow in 19 of 58 (33%) SS patients, compared with 1 of
19 (5%) EID patients (sensitivity ¼ 33%; specificity ¼ 95%).
The results (including expression of CD158a and CD158b)
are summarized in Table 2.
No major difference was observed in the expression of
CD27, CD45RA, and CD45RO by CD4þ T cells between SS
and EID patients (data not shown).
Copy number variation
Copy number variation (CNV) experiments were performed
in 58 SS patients and 17 EID patients in Leiden. Duplicate
experiments for 14 samples were performed in London,
which gave identical results (see Supplementary Figure S1
online).
In 47 of 58 (81%) SS patients, alterations in copy number
were found compared with none of the 17 EID patients. Gain
of MYC was observed in 23 of 58 (40%) SS patients
(sensitivity ¼ 40%, specificity ¼ 100%).MNT loss was found
in 38 of 58 (66%) SS patients (sensitivity ¼ 66%, specificity ¼
100%) and one (2%) patient showed gain of MNT (Figure 1).
Gain ofMYC and/or loss ofMNTwas found in 76% (44 of 58)
of SS patients (sensitivity ¼ 76%, specificity ¼ 100%). Copy
number alterations of JUNB and TWIST1 were found in only
a minority of SS patients (Figure 1).
Gene expression
Gene expression (GE) analysis were performed on 55 SS, 19
EID, and 4 healthy control patients in Leiden. Thirty samplesTable 2. Overview of the tested flow cytometry markers
Markers for SS Described in
the Literature
SS Patients, n/total
(n [ 59)
CD4/CD8 ratio 10 46/53
CD4þCD7  40% 32/591
CD4þCD26  30% 51/592
CD158a3 2/58
CD158b3 13/59
CD158k3 19/58
Abbreviations: EID, erythrodermic inflammatory dermatoses; SS, Se´zary syndro
1Including four of seven SS patients with a CD4/CD8 ratio below 10.
2Including five of seven SS patients with a CD4/CD8 ratio below 10.
3Low expression and expression of 5% or more of the CD4þ lymphocytes.
Journal of Investigative Dermatology (2016), Volume 136were also analyzed in London, with identical results in 28
samples (see Supplementary Figure S2 online); two samples
could not be analyzed because of a technical error.
DNM3, TWIST1, EPHA4, PLS3, and STAT4 were the most
differentially expressed genes in SS patients compared with
EID patients and healthy controls with 100% specificity (P <
0.001) (Table 3, see Supplementary Figure S3 online). Up-
regulation of DNM3, TWIST1, EPHA4, and PLS3 was found
in 6675% of SS patients, and STAT4 was down-regulated in
91% of SS patients (Figure 2). Up-regulation of DNM3,
TWIST1, EPHA4, and PLS3 was found in 41 of 55 (75%), 38
of 55 (69%), 36 of 55 (66%), 36 of 55 (66%) of SS patients,
respectively, and STAT4 was down-regulated in 50 of 55
(91%) of SS patients. Combining alterations in gene expres-
sion (STAT4, TWIST1, and DNM3 or STAT4, TWIST1, and
PLS3), we could distinguish 54 of 55 (98%) SS patients from
all EID patients (sensitivity ¼ 98%, specificity ¼ 100%).
Aberrant gene expression of CDO1, TRAIL, CD1D,
GATA3, MYC, and JUNB was found in only a minority of SS
patients (Table 3).
DISCUSSION
In the present multicenter study, we investigated the diag-
nostic sensitivity and specificity of immunophenotypic and
molecular biomarkers in SS using SOPs. We show that by
using SOPs, it is possible to obtain highly reproducible results
for flow cytometry, CNV, and GE analysis and show that loss
of CD7 and CD26 by CD4þ T cells; gain in copy number of
MYC and loss of MNT; increased expression of DNM3,
TWIST1, EPHA4, and PLS3; and decreased expression of
STAT4 are highly characteristic for Se´zary cells.
In the current study most SS patients have a CD4/CD8 ratio
above 10, but we also show that a significant minority of
patients (13%) does not fulfill this diagnostic criterion. For
these patients additional immunophenotypic markers are
clearly needed.
Comparison of results from previous flow cytometry studies
is hindered by the use of different protocols and cell pop-
ulations. In the present study we focused on CD4þ gated T
cells because CD4 is rarely lost by Se´zary cells, facilitating
the comparison of expression levels of different immuno-
phenotypic markers.
Previous studies reported that a CD4þCD26 cell popu-
lation greater than 30% had a sensitivity of 97% and speci-
ficity of 100% in diagnosing peripheral blood involvementin 59 SS and 19 EID patients at inclusion of the study
EID Patients,
n/total (n [ 19)
Sensitivity,
%
Specificity,
%
1/12 87 92
0/19 54 100
10/19 86 47
0/19 3 100
1/19 22 95
1/19 33 95
me.
Figure 1. Copy number variation
results for JUNB, TWIST1, MNT, and
MYC. The gains and losses in copy
number in 58 Se´zary syndrome
compared with 17 erythrodermic
inflammatory dermatoses patients are
shown as normalized relative copy
number, where 2 represents diploid
DNA. The dotted lines signify the
chosen thresholds for gain and loss,
2.5 and 1.5, respectively.
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terion for SS (Bernengo et al., 2001; Vonderheid and
Bernengo, 2003). Indeed, loss of CD26 in more than 30%
of CD4þ T cells was found in 86% of SS patients but also in
53% of EID patients, resulting in a specificity of 47%.
However, when using a percentage of 80% as the cut-off
point, we found that 39 of 59 (66%) SS patients but none
of the EID patients met this criterion.Table 3. Results of aberrant gene expression in all
tested genes in 55 SS patients relative to 19 EID
patients and 4 healthy control subjects1
Gene (Up-Regulation or
Down-Regulation)
SS, n/total
(n [ 55)
Sensitivity,
%
PLS3 36/55 66
DNM3 41/55 75
CDO1 20/55 36
TRAIL 4/55 7
CD1D 6/55 11
GATA3 2/55 4
MYC 0/55 0
JUNB 9/55 16
TWIST1 38/55 69
EPHA4 36/55 66
STAT4 50/55 91
Abbreviations: EID, erythrodermic inflammatory dermatoses; SS, Se´zary
syndrome.
1With the receiver operating characteristic curve analysis, a threshold was
established at a specificity of 100% and an accuracy above 0.80. PLS3,
DNM3, TWIST1, EPHA4, and STAT4 were found to be useful diagnostic
markers in SS.These discrepant results can be explained by different flow
cytometry protocols. We evaluated CD26 expression on
CD4þ gated T cells, whereas Bernengo et al. looked at
CD4þCD26 cells on gated total lymphocytes. Indeed, when
looking at the CD4þCD26 cells of 30% or more on total
lymphocytes, similar results were found (sensitivity ¼ 80%,
specificity ¼ 95%; data not shown).
A level of CD4þCD7 cells of more than 40% has also
been suggested as a tentative criterion in the diagnosis of SS
(Vonderheid et al., 2002). Consistent with the literature, we
found that loss of CD7 above 40% of the CD4þ T cells is
highly specific (specificity ¼ 100%) but is not a sensitive
marker (sensitivity ¼ 54%) (Harmon et al., 1996; Nagler
et al., 2012; Vonderheid and Bernengo, 2003). Similar re-
sults were found for 40% or more CD4þCD7 cells on total
lymphocytes (sensitivity ¼ 42%, specificity ¼ 100%; data not
shown).
Flow cytometry results show that in 83% of SS patients,
CD4þ T cells display loss of CD26 by more than 80% and/or
loss of CD7 by more than 40%, whereas this was never
observed in EID patients. These observations are relevant
because they can readily be included in immunophenotypic
testing of erythrodermic patients.
Previous studies reported expression of killer cell
immunoglobulin-like receptor CD158k in 6597% of SS
patients (Bahler et al., 2008; Klemke et al., 2008;
Poszepczynska-Guigne et al., 2004). Flow cytometry anal-
ysis, performed in both Leiden and Paris, showed expression
of CD158k in only 33% of SS patients (19 of 58), and in most
of these SS patients (18 of 19) the CD158k antigen was
expressed at low levels. This discrepancy can be explained bywww.jidonline.org 1367
Figure 2. Gene expression results for
DNM3, TWIST1, EPHA4, PLS3, and
STAT4.The differential gene
expression is shown as relative
normalized messenger RNA levels in
55 Se´zary syndrome patients
compared with 19 patients with
erythrodermic inflammatory
dermatoses and 4 healthy control
subjects. ****Statistically significant
difference in gene expression in
Se´zary syndrome compared with
erythrodermic inflammatory
dermatoses and healthy control
subjects (P < 0.001). The dotted lines
represent the thresholds for differential
expression, determined with receiver
operating characteristic curves with a
specificity of 100%. The y-axis
represents the relative messenger RNA
expression with varying scale in all
figures. EID, erythrodermic
inflammatory dermatoses; HC, healthy
control; mRNA, messenger RNA; SS,
Se´zary syndrome.
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1368the fact that the present study was performed on frozen pe-
ripheral blood mononuclear cells (PBMCs) instead of freshly
isolated PBMCs. Indeed, a recent study on freshly isolated
PBMCs from SS patients showed high CD158k expression in
Se´zary cells (Moins-Teisserenc et al., 2015).
For CNV and GE analysis the use of SOPs and custom-
made PCR platforms led to highly reproducible results as
well. Gain of MYC and/or loss of its antagonist MNT was
found in 76% of SS patients but never in EID patients. Gain of
TWIST1 and JUNB was detected in only a small minority of
SS patients.
In line with the literature, we found up-regulation ofDNM3,
TWIST1, EPHA4, and PLS3 and down-regulation of STAT4 in
most SS patients (Booken et al., 2008; Goswami et al., 2012;
Kari et al., 2003; Nebozhyn et al., 2006; Su et al., 2003; Van
Doorn R. et al., 2004). In contrast, only a minority of SSJournal of Investigative Dermatology (2016), Volume 136patients showed up-regulation of GATA3, CD1D, TRAIL,
CDO1, JUNB, and MYC, implying that these genes are not
useful diagnostic markers. Why gain ofMYC and loss ofMNT,
which is observed in most patients, does not lead to up-
regulation of MYC expression is as yet unexplained.
Combined alterations in gene expression of STAT4, TWIST1,
and DNM3 or STAT4, TWIST1, and PLS3 could distinguish
98% of SS patients from EID patients, suggesting that this
diagnostic panel will be useful as an additional molecular
criterion in the diagnostic differentiation between SS and EID.
In the present study 27 patients were diagnosed with SS
before inclusion in the study. However, no significant
differences were found in the prevalence of the
previously described markers between the 27 patients
already diagnosed with SS before inclusion in the study
and the 32 SS patients newly diagnosed at time of inclusion
SE Boonk et al.
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lence of investigated markers was similar in the 36 SS patients
who received treatment during sample collection at inclusion
and the 23 SS patients who did not receive any form of
treatment (see Supplementary Table S2 online). These ob-
servations argue that the observed immunophenotypic and
molecular changes are stably expressed in Se´zary cells.
We show that standardization of flow cytometry, CNV, and
GE procedures leads to strong reproducibility of results. We
argue that to facilitate comparison of results from different
centers, it will be important to closely define the subset of
cells that was investigated, and based on the present study we
suggest gating on CD4þ T cells in future studies.
For patients in whom the distinction between SS and EID
still cannot be made using the current diagnostic criteria, we
propose that these two additional diagnostic panels can be
used: (i) loss of CD26 (80% CD4þ T cells) and/or loss of
CD7 (40% CD4þ T cells) for immunophenotypic analysis
and (ii) combination of altered gene expression of STAT4,
TWIST1, and DNM3 or STAT4, TWIST1, and PLS3 for mo-
lecular analysis.
MATERIALS AND METHODS
Design of the study
To achieve sufficient power for the study, a consortium of six Euro-
pean Organization for Research and Treatment of Cancer centers
with extensive experience with SS was formed including centers
from Helsinki, Finland; London, England; Leiden, The Netherlands;
Mannheim, Germany; Turin, Italy; and Paris, France. At time of in-
clusion peripheral blood samples were collected for investigation of
(i) expression of cell surface proteins by flow cytometry, (ii) CNV,
and (iii) GE profiles. The markers were selected based on the liter-
ature and are presented in Supplementary Table S3 online.
To optimize standardization and to prevent interdepartmental
differences, SOPs were produced for the workflow of blood sam-
pling, isolation of PBMCs, and enrichment for CD4þ T cells (SOP
001), DNA isolation (SOP 002), RNA isolation (SOP 003), comple-
mentary DNA synthesis (SOP 004), CNV and GE assays (SOP 005),
flow cytometry experiments (SOP 007), and the freezing and ship-
ment of samples (SOP 008) (see Supplementary Figure S4 and
Supplementary Materials online). Much effort was put into stan-
dardizing flow cytometry analysis, because this technique has been
shown to have limited reproducibility in multicenter studies because
of limited standardization of laboratory procedures, instrumental
settings, and interpretation of results (van Dongen et al., 2012;
Westers et al., 2012).
To test if the use of SOPs leads to increased reproducibility, the
flow cytometry experiments were performed in duplicate in Leiden
and Paris on all samples, and assays for CNV and GE were performed
in Leiden and repeated in London for a selected number of samples.
In all participating centers the study was approved by the local
institutional ethical review boards, and written informed patient
consent was obtained. Consensus meetings to compare experi-
mental results were held on August 31, 2012, in Paris and October
31, 2013, in Leiden.
Patient selection and clinical characteristics
Between September 2009 and October 2013 a total of 103 subjects
were enrolled with the following diagnosis: SS (n ¼ 72), EID (n ¼
27), and healthy controls (n ¼ 4).Inclusion criteria for the SS patients were diagnosis of SS based on
the recent World Health Organization-European Organization for
Research and Treatment of Cancer criteria and available complete
clinical data. Inclusion criteria for patients with EID were presen-
tation with erythroderma and blood test results not meeting the SS
blood criteria.
From the initial 72 patients with SS 13 were excluded because of
inferior sample quality (n ¼ 10) or insufficient clinical data (n ¼ 3).
From the initial 27 EID patients eight were excluded because of
inferior sample quality (n ¼ 3) or insufficient clinical data (n ¼ 5).
The final study group consisted of 59 patients with SS, 19 patients
with EID, and four healthy controls. The SS group consisted of 32
patients with newly diagnosed SS and 27 patients with known SS.
Thirty-six SS patients received treatment at the time of blood sam-
pling (10 newly diagnosed with SS and 26 with known SS). The
treatment consisted of psoralen plus UVA therapy (n ¼ 2), extra-
corporeal photopheresis as monotherapy or combined with immu-
nomodulatory agents (n ¼ 12), prednisone alone or in combination
with chlorambucil (n ¼ 9), monotherapy with interferon alfa, bex-
arotene, methotrexate, or acitretin (n ¼ 11), and polychemotherapy
(n ¼ 2).
The EID group included nine patients with atopic erythroderma,
five patients with erythrodermic psoriasis, two patients with eryth-
rodermic drug eruption, two patients with idiopathic erythroderma,
and one patient with paraneoplastic erythroderma secondary to a
cholangiocarcinoma. None of the EID patients developed a lym-
phoma during follow-up study (median follow-up ¼ 22 months,
range ¼ 8e38 months).
Workup blood samples
PBMCs were isolated from peripheral blood and stored in liquid- or
vapor-phase nitrogen. Part of the fresh PBMCs were enriched for
CD4þ T helper cells by depletion of non-CD4þ T cells, resulting in
greater than 95% purity for the CD4þ T-cell population, using the
CD4þ T Cell Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach,
Germany) for CNV and GE assays.
Genomic DNAwas extracted using the QIAamp DNA Blood Mini
Kit (Qiagen, Hilden, Germany) and stored at e20C.
RNA was isolated using the RNeasy Mini Kit (Qiagen), which
included on-column DNase digestion. Two mg of RNA was reverse-
transcribed in triplicate with the High Capacity cDNA Reverse
Transcription Kit with RNase Inhibitor (Applied Biosystems, Foster
City, CA, USA), using random priming in a final volume of 20 mL.
After synthesis, complementary DNA samples were stored at e20C.
A detailed description of this workup of blood samples is found in
the Supplementary Materials (SOPs 001e004 and 008).
Flow cytometry
In Leiden and Paris flow cytometry was performed for the following
antigens: CD2, CD3, CD4, CD5, CD7, CD8, CD26, CD27,
CD45RA, CD45RO, CD158a, CD158b, and CD158k, including
isotype-specific controls (see Supplementary Table S4 online and
SOP 007 in the Supplementary Materials). Lymphocytes were gated
from forward and sideward scatter patterns; next, antigen expression
was assayed from CD4þ gated lymphocytes. Specific antigen
expression was observed relative to autofluorescence and (non-)
specific signals obtained from each individual patient and a PBMC
control sample. Specific antigen expression was observed relative to
autofluorescence and (non-) specific signals, as determined with
unlabelled cells, isotype-specific control and epitope-specific
labelling relatively, from each individual patient and a PBMC controlwww.jidonline.org 1369
Figure 3. Interpretation of flow
cytometry results. (a) A single peak
located on the right side of the
determined threshold represents a
single population with positive
staining for CD7 in 97% of the gated
cells. (b) Two distinct populations of
the gated cells, in which 47% of the
cells show positive expression for CD7
and 53% show negative staining. (c)
Diminished expression for CD7 of a
single population of gated cells,
surrounding a determined threshold,
is indicated as dim. (d). The specific
CD158k antigen expression signal
(indicated in red) is slightly shifted to
the right compared with its
autofluorescence and isotype control
signals (green and blue lines),
indicated in yellow. This shows that
the gated cells do express CD158k but
at very low level, indicated as “low.”
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and functioned as an internal reference sample for each flow
cytometry session. Samples were analyzed in a blinded setting.
Specific antigen expression in the population of gated cells
(expression or loss) was displayed in percentages (Figure 3a and b).
Antigen expression was considered dim if all gated cells showed
diminished expression around the determined threshold (Figure 3c).
For CD158a, CD158b, and CD158k, expression below 5% of the
gated cells was considered as no expression, but when intermediate
expression of a single population of gated cells, surrounding a
determined threshold, was found, this was characterized as low-
expressing antigen (for example, CD158klow) (Figure 3d).
CNV assay
Quantitative PCR assays with 6-Carboxyfluorescein-labeled hydro-
lysis Minor Groove Binder probes (Life Technologies, Carlsbad, CA)
were developed for target genes JUNB, TWIST1, MYC, and MNT
and reference genes ABT1, ARG2, and DNM3 (see Supplementary
Table S5 online). Reference genes were selected from different
large copy number-stable chromosomal regions in SS, selected from
array-based comparative genomic hybridization experiments on 20
SS samples (Vermeer et al., 2008). Amplification efficiency was
evaluated in triplicate, using eight 4-fold serial dilution points
ranging from 3 ng/mL to 183 fg/mL DNA concentration, under opti-
mized primer and hydrolysis probe concentrations. Assays with
amplification efficiency value between 90% and 100% and aJournal of Investigative Dermatology (2016), Volume 136correlation coefficient above 0.98 were accepted for CNV analysis.
Assays were performed on custom-made PCR plates (Life Technol-
ogies) following SOP 005 (see Supplementary Materials).
Data were normalized against reference genes and relative to the
common reference using the DDCq method and are presented as
relative copy number, where 2 stands for diploid DNA (Livak and
Schmittgen, 2001). The following thresholds were maintained for
the CNV data: 1.5e2.5 was considered as diploid (normal) DNA,
greater than 2.5 as gain in copy number, and less than 1.5 as loss
in copy number.
GE assay
GE quantitative PCR assays with FAM-labelled hydrolysis MGB
probes (Life Technologies) were developed and validated, as
described for CNV quantitative PCR assays, for target genes PLS3,
DNM3, CDO1, TRAIL, CD1D, GATA3, MYC, JUNB, TWIST1,
EPHA4, and STAT4 and reference genes ARF5, ERCC3, and
TMEM87A (see Supplementary Table S5). Stably expressed reference
genes were selected from microarray experiments on SS samples and
validated in SS and EID samples according to the GeNorm method
(Booken et al., 2008; Vandesompele et al., 2002; Van Doorn R.
et al., 2004). Assays were performed on custom-made PCR plates
(Life Technologies) following SOP 005. Receiver operating charac-
teristic curve analyses were used to determine fixed cut-off thresh-
olds for each individual gene expression quantitative PCR assay with
a specificity of 100% and an accuracy above 0.80. A one-tailed
SE Boonk et al.
Diagnostic Markers in Se´zary SyndromeMann-Whitney test was applied to test for significant differential
expression between the SS and EID samples. P-values below 0.05
were regarded as statistically significant.
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